Akash Tewari

Cory Kasimov

Olivia Brayer

Paul Matteis

Jessica Fye

Konstantinos Biliouris

Philip Nadeau

Salveen Richter

Adam Ferrari

Alexandria Hammond

Allison Bratzel

Andrea Park

Christopher Raymond

Eliana Merle

Ellen Horste

Gena Wang

Huidong Wang

Jasmine Fels

Jason Gerberry

Joseph Schwartz

Kostas Biliouris

Mohit Bansal

Sean Laaman

Tommie Reerink

Alex Hammond

Ellie Merle

John Wang

Julian Pino

Sadia Rehman

Vikram Purohit

- BioMarin Pharmaceutical Inc. is prioritizing its **BMN 333 program** for achondroplasia, with a combined Phase 2/3 study planned to start in patients in the **first half of next year**, aiming for superiority over Voxzogo.  **[1048477_tx_379960_0]** **[1048477_tx_379960_4]** **[1048477_tx_379960_5]** 
- The company expects to release **hypochondroplasia data for Voxzogo** and **BMN 401 (ENPP1 deficiency) ENERGY3 study data** in the **first half of next year** and **first quarter of next year**, respectively.  **[1048477_tx_379960_0]** **[1048477_tx_379960_7]** 
- BioMarin is also filing for **Palynziq in adolescents** in the U.S. and Europe, representing a significant opportunity to expand the label.  **[1048477_tx_379960_0]** 
- The company is actively pursuing **business development opportunities** for both early and late-stage assets, leveraging its **cash position** and focusing on genetically defined conditions, skeletal conditions, and enzyme replacement therapies.  **[1048477_tx_379960_0]** **[1048477_tx_379960_1]**

BioMarin Pharmaceutical Inc. Discusses Key R&D Priorities and Pipeline Progress

BIOMARIN PHARMACEUTICAL (BMRN)